NCCN  ||| S:0 E:5 ||| NNP
Task  ||| S:5 E:10 ||| NNP
Force  ||| S:10 E:16 ||| NNP
Report ||| S:16 E:22 ||| NNP
:  ||| S:22 E:24 ||| :
Specialty  ||| S:24 E:34 ||| NNP
Pharmacy  ||| S:34 E:43 ||| NNP
The  ||| S:43 E:47 ||| DT
use  ||| S:47 E:51 ||| NN
of  ||| S:51 E:54 ||| IN
specialty  ||| S:54 E:64 ||| NN
pharmacies  ||| S:64 E:75 ||| NN
is  ||| S:75 E:78 ||| VBZ
expanding  ||| S:78 E:88 ||| VBG
in  ||| S:88 E:91 ||| IN
oncology  ||| S:91 E:100 ||| JJ
pharmacy  ||| S:100 E:109 ||| JJ
practice ||| S:109 E:117 ||| NN
.  ||| S:117 E:119 ||| .
Specialty  ||| S:119 E:129 ||| NN
pharmacies  ||| S:129 E:140 ||| NNS
provide  ||| S:140 E:148 ||| VBP
a  ||| S:148 E:150 ||| DT
channel  ||| S:150 E:158 ||| NN
for  ||| S:158 E:162 ||| IN
distributing  ||| S:162 E:175 ||| VBG
drugs  ||| S:175 E:181 ||| NNS
that ||| S:181 E:185 ||| WDT
,  ||| S:185 E:187 ||| ,
from  ||| S:187 E:192 ||| IN
the  ||| S:192 E:196 ||| DT
payor  ||| S:196 E:202 ||| JJ
perspective ||| S:202 E:213 ||| NN
,  ||| S:213 E:215 ||| ,
creates  ||| S:215 E:223 ||| VBZ
economies  ||| S:223 E:233 ||| NNS
of  ||| S:233 E:236 ||| IN
scale  ||| S:236 E:242 ||| NN
and  ||| S:242 E:246 ||| CC
streamlines  ||| S:246 E:258 ||| VBG
the  ||| S:258 E:262 ||| DT
delivery  ||| S:262 E:271 ||| NN
of  ||| S:271 E:274 ||| IN
expensive  ||| S:274 E:284 ||| JJ
drugs ||| S:284 E:289 ||| NNS
.  ||| S:289 E:291 ||| .
Proposed  ||| S:291 E:300 ||| JJ
goals  ||| S:300 E:306 ||| NNS
of  ||| S:306 E:309 ||| IN
specialty  ||| S:309 E:319 ||| NN
pharmacy  ||| S:319 E:328 ||| NNS
include  ||| S:328 E:336 ||| VBP
optimization  ||| S:336 E:349 ||| VBN
of  ||| S:349 E:352 ||| IN
pharmaceutical  ||| S:352 E:367 ||| JJ
care  ||| S:367 E:372 ||| NN
outcomes  ||| S:372 E:381 ||| NNS
through  ||| S:381 E:389 ||| IN
ensuring  ||| S:389 E:398 ||| VBG
appropriate  ||| S:398 E:410 ||| JJ
medication  ||| S:410 E:421 ||| NN
use  ||| S:421 E:425 ||| NN
and  ||| S:425 E:429 ||| CC
maximizing  ||| S:429 E:440 ||| JJ
adherence ||| S:440 E:449 ||| NN
,  ||| S:449 E:451 ||| ,
and  ||| S:451 E:455 ||| CC
optimization  ||| S:455 E:468 ||| NN
of  ||| S:468 E:471 ||| IN
economic  ||| S:471 E:480 ||| JJ
outcomes  ||| S:480 E:489 ||| NNS
through  ||| S:489 E:497 ||| IN
avoiding  ||| S:497 E:506 ||| VBG
unwarranted  ||| S:506 E:518 ||| JJ
drug  ||| S:518 E:523 ||| NN
expenditure ||| S:523 E:534 ||| NN
.  ||| S:534 E:536 ||| .
In  ||| S:536 E:539 ||| IN
oncology  ||| S:539 E:548 ||| JJ
practice ||| S:548 E:556 ||| NN
,  ||| S:556 E:558 ||| ,
specialty  ||| S:558 E:568 ||| NN
pharmacies  ||| S:568 E:579 ||| NNS
have  ||| S:579 E:584 ||| VBP
become  ||| S:584 E:591 ||| VBN
a  ||| S:591 E:593 ||| DT
distribution  ||| S:593 E:606 ||| NN
channel  ||| S:606 E:614 ||| NN
for  ||| S:614 E:618 ||| IN
various  ||| S:618 E:626 ||| JJ
agents ||| S:626 E:632 ||| NNS
.  ||| S:632 E:634 ||| .
The  ||| S:634 E:638 ||| DT
use  ||| S:638 E:642 ||| NN
of  ||| S:642 E:645 ||| IN
a  ||| S:645 E:647 ||| DT
specialty  ||| S:647 E:657 ||| NN
pharmacy ||| S:657 E:665 ||| NN
,  ||| S:665 E:667 ||| ,
and  ||| S:667 E:671 ||| CC
the  ||| S:671 E:675 ||| DT
addition  ||| S:675 E:684 ||| NN
of  ||| S:684 E:687 ||| IN
the  ||| S:687 E:691 ||| DT
pharmacist  ||| S:691 E:702 ||| NN
from  ||| S:702 E:707 ||| IN
the  ||| S:707 E:711 ||| DT
specialty  ||| S:711 E:721 ||| NN
pharmacy  ||| S:721 E:730 ||| NN
to  ||| S:730 E:733 ||| TO
the  ||| S:733 E:737 ||| DT
health  ||| S:737 E:744 ||| NN
care  ||| S:744 E:749 ||| NN
team ||| S:749 E:753 ||| NN
,  ||| S:753 E:755 ||| ,
may  ||| S:755 E:759 ||| MD
not  ||| S:759 E:763 ||| RB
only  ||| S:763 E:768 ||| RB
provide  ||| S:768 E:776 ||| VB
benefits  ||| S:776 E:785 ||| NNS
for  ||| S:785 E:789 ||| IN
care  ||| S:789 E:794 ||| NN
but  ||| S:794 E:798 ||| CC
also  ||| S:798 E:803 ||| RB
present  ||| S:803 E:811 ||| JJ
challenges  ||| S:811 E:822 ||| NNS
in  ||| S:822 E:825 ||| IN
oncology  ||| S:825 E:834 ||| JJ
practice ||| S:834 E:842 ||| NN
.  ||| S:842 E:844 ||| .
The  ||| S:844 E:848 ||| DT
NCCN  ||| S:848 E:853 ||| NNP
Specialty  ||| S:853 E:863 ||| NNP
Pharmacy  ||| S:863 E:872 ||| NNP
Task  ||| S:872 E:877 ||| NNP
Force  ||| S:877 E:883 ||| NNP
met  ||| S:883 E:887 ||| VBD
to  ||| S:887 E:890 ||| TO
identify  ||| S:890 E:899 ||| VB
and  ||| S:899 E:903 ||| CC
examine  ||| S:903 E:911 ||| VB
the  ||| S:911 E:915 ||| DT
impact  ||| S:915 E:922 ||| NN
of  ||| S:922 E:925 ||| IN
specialty  ||| S:925 E:935 ||| NN
pharmacy  ||| S:935 E:944 ||| NN
practice  ||| S:944 E:953 ||| NN
on  ||| S:953 E:956 ||| IN
the  ||| S:956 E:960 ||| DT
care  ||| S:960 E:965 ||| NN
of  ||| S:965 E:968 ||| IN
people  ||| S:968 E:975 ||| NNS
with  ||| S:975 E:980 ||| IN
cancer ||| S:980 E:986 ||| NN
,  ||| S:986 E:988 ||| ,
and  ||| S:988 E:992 ||| CC
to  ||| S:992 E:995 ||| TO
provide  ||| S:995 E:1003 ||| VB
recommendations  ||| S:1003 E:1019 ||| NNS
regarding  ||| S:1019 E:1029 ||| VBG
issues  ||| S:1029 E:1036 ||| NNS
discussed ||| S:1036 E:1045 ||| VBN
.  ||| S:1045 E:1047 ||| .
This  ||| S:1047 E:1052 ||| DT
report  ||| S:1052 E:1059 ||| NN
provides  ||| S:1059 E:1068 ||| VBZ
recommendations  ||| S:1068 E:1084 ||| NNS
within  ||| S:1084 E:1091 ||| IN
the  ||| S:1091 E:1095 ||| DT
following  ||| S:1095 E:1105 ||| JJ
categories ||| S:1105 E:1115 ||| NNS
:  ||| S:1115 E:1117 ||| :
education  ||| S:1117 E:1127 ||| NN
and  ||| S:1127 E:1131 ||| CC
training  ||| S:1131 E:1140 ||| NN
of  ||| S:1140 E:1143 ||| IN
specialty  ||| S:1143 E:1153 ||| NN
pharmacy  ||| S:1153 E:1162 ||| NN
practitioners  ||| S:1162 E:1176 ||| NNS
who  ||| S:1176 E:1180 ||| WP
care  ||| S:1180 E:1185 ||| VBP
for  ||| S:1185 E:1189 ||| IN
individuals  ||| S:1189 E:1201 ||| NNS
with  ||| S:1201 E:1206 ||| IN
cancer ||| S:1206 E:1212 ||| NN
,  ||| S:1212 E:1214 ||| ,
coordination  ||| S:1214 E:1227 ||| NN
of  ||| S:1227 E:1230 ||| IN
care ||| S:1230 E:1234 ||| NN
,  ||| S:1234 E:1236 ||| ,
and  ||| S:1236 E:1240 ||| CC
patient  ||| S:1240 E:1248 ||| JJ
safety ||| S:1248 E:1254 ||| NN
.  ||| S:1254 E:1256 ||| .
Areas  ||| S:1256 E:1262 ||| NNS
for  ||| S:1262 E:1266 ||| IN
further  ||| S:1266 E:1274 ||| JJ
evaluation  ||| S:1274 E:1285 ||| NN
are  ||| S:1285 E:1289 ||| VBP
also  ||| S:1289 E:1294 ||| RB
identified ||| S:1294 E:1304 ||| VBN
.  ||| S:1304 E:1306 ||| .
